Genetically engineered ErbB2 overexpression sensitizes organoid-derived tumors to checkpoint inhibition in a syngeneic model of gastric cancer
The combined data indicate that ErbB2, perhaps by driving micronuclei formation, has immunogenic properties that manifest in the form of increased T-cell infiltration and expansion, which can be exploited therapeutically by combining PD1-directed checkpoint blockade with ErbB2-targeted therapy.
Authors
- Jiazhuo He
- Chiara F. Magnani (ORCID: https://orcid.org/0000-0003-2474-2159)
- Francesco Manfredi (ORCID: https://orcid.org/0000-0003-2409-944X)
- Peter Leary (ORCID: https://orcid.org/0000-0003-1430-6185)
- Zuzana Naščáková (ORCID: https://orcid.org/0000-0003-2035-8061)
- Flora Azizi
- G Papa
- Lydia Kirsche (ORCID: https://orcid.org/0009-0002-1826-3952)
- Anne Müller
Institutions
- University of Zurich (CH)
- University Hospital of Zurich (CH)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-012976
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 0.00